US EditionAspen Neuroscience to Present at American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
- Dr. Xiaokui Zhang, Chief Scientific Officer at Aspen Neuroscience, is scheduled to present on autologous iPSC-based neuron replacement therapy for Parkinson’s disease at the ASGCT 28th Annual Meeting, taking place in New Orleans from May 13 to 17, 2025.
- The presentation follows Aspen's clinical development of personalized, patient-derived cell therapies, including ANPD001, within a Phase 1/2a trial targeting high unmet medical needs in Parkinson's disease.
- Aspen develops these therapies on a best-in-class platform combining cell biology, machine learning, and genomics with in-house bioinformatics, manufacturing, and quality control capabilities.
- Dr. Zhang expressed enthusiasm about participating in the event focused on recent progress in cell and gene therapy, highlighting ASGCT's commitment to turning these therapeutic breakthroughs into safe and effective treatments for patients.
- At the premier international conference for professionals in cell and gene therapies, Aspen Neuroscience showcased its progress in developing autologous neuron replacement treatments for Parkinson’s disease aimed at enhancing patient outcomes.
Insights by Ground AI
Does this summary seem wrong?
39 Articles
39 Articles
All
Left
3
Center
12
Right
Coverage Details
Total News Sources39
Leaning Left3Leaning Right0Center12Last UpdatedBias Distribution80% Center
Bias Distribution
- 80% of the sources are Center
80% Center
L 20%
C 80%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
